The abstract is read at the publisher; the summary is JClub's.
In SHIV-infected macaques, FcγR-engaging Fc variants of 3BNC117 produce durable, CD8 T cell–dependent remission lasting nearly 300 weeks, unlike FcγR-null variants.
- Why it matters: ART interruption control after bNAb therapy has been observed, but the host mechanisms behind these “vaccinal” effects are unresolved.
- What they did: In the RIO trial–inspired approach, macaques received brief anti-HIV-1 antibody treatment during acute infection using Fc domain variants of 3BNC117 matched for binding, neutralization, and pharmacokinetics but differing in FcγR engagement.
- The result: FcγR engagement imprinted CD8 responses with enhanced effector function, early clonal focusing with sustained clonotype persistence, and distinct transcriptional signatures, yielding suppression in every evaluable animal (nearly 300 wk) versus only one of eight with the FcγR-null variant.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.